Progress of prevention and cure of chemoradiotherapy-related hepatitis B virus reactivation

Abstract

WANG Meng-Sen, YU Yong-Hua. Progress of prevention and cure of chemoradiotherapy-related hepatitis B virus reactivation[J]. Journal of International Oncology, 2014, 41(3): 184-187.

［1］ Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in Chinadeclining HBV prevalence due to hepatitis B vaccination［J］. Vaccine, 2009, 27(47):65506557. ［2］ Chen WQ. Estimation of cancer incidence and mortality in China 20042005［J］. Chin J Oncol, 2009, 31(9):664668. ［3］ Wands J, Chura CM, Roll FJ, et al. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders［J］. Gastroenterology, 1975, 68(1):105112. ［4］ Yeo W, Chan PK, Zhong S, et al. Frequency of Hepatitis B Virus reactivation in cancer patients undergoing cykotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors［J］. J Med Viorl, 2000, 62(3):299307. ［5］ Kawsar HI, Shahnewaz J, Gopalakrishna KV, et al. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis［J］. Clin Adv Hematol Oncol, 2012, 10(6):370378. ［6］ Post A, Nagendra S. Reactivation of hepatitis B: pathogenesis and clinical implications［J］. Curr Infect Dis Rep, 2009, 11(2):113119. ［7］ Jang JW, Kwon JH, You CR, et al. Risk of HBV reactmation according to viral status and treatment intensity in patients with hepatocellular carcinoma［J］. Antivir Ther, 2011, 16(7):969977. ［8］ Ling WH, Soe PP, Pang AS, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours［J］. Br J Cancer, 2013, 108(10):19311935. ［9］ Niitsu N, Hagiwara Y, Tanae K, et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large Bcell lymphoma after rituximab combination chemotherapy［J］. J Clin Oncol, 2010, 28(34):50975100. ［10］ Yeo W, Chan TC, Leung NW, et al.Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab［J］.J Clin Oncol, 2009, 27, 605611. ［11］ Sema Sezgin G, Bilal S, Coskun HS. Hepatitis B reactivation related to everolimus ［J］. World J Hepatol, 2013, 5(1):4345. ［12］ Fujimoto Y, Hashimoto N, Kinoshita M, et al. Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis［J］. Int J Clin Oncol, 2012, 17(3):290293. ［13］ Ohno M, Narita Y, Miyakita Y, et al.Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide—case report［J］. Neurol Med Chir (Tokyo), 2011, 51(10):728731. ［14］ Kim IK, Kim BG, Kim W, et al. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virusinfected patients undergoing cytotoxic chemotherapy for malignancy［J］. Antimicrob Agents Chemother， 2012, 56(11):55115519. ［15］ Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version)［J］. Zhonghua Liu Xing Bing Xue Za Zhi， 2011, 32(4):405415. ［16］ European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection［J］. J Hepatol, 2012, 57(1):167185. ［17］ Wong V, Chan H. Chronic hepatitis B: a treatment update［J］. Semin Liver Dis, 2013, 33(2):122129. ［18］ Yun J, Kim KH, Kang ES, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in postoperative breast cancer patients receiving anthracycline based adjuvant chemotherapy［J］. Br J Cancer, 2011, 104(4):559563. ［19］ Chen XQ, Peng JW, Lin GN,et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAgpositive patients with diffuse large Bcell lymphoma undergoing prolonged rituximab therapy［J］. Med Oncol, 2012, 29(2):12371241. ［20］ Kim JH, Park JW, Kim TH, et al. Hepatitis B virus reactivation after threedimensional conformal radiotherapy in patients with hepatitis B virusrelated hepatocellular［J］. Int J Radiat Oncol Biol Phys, 2007, 69(3):813819. ［21］ Marcellin P, Chang TT, Lim SG, et al. Longterm efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigenpostitive chronic hepatitis B［J］. Hepatology, 2008, 48(3):750758. ［22］ Chen FW, Coyle L, Jones BE, et al. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease［J］. Liver Int, 2013, 33(8):12031210. ［23］ Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in Bcell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group［J］. Eur J Cancer, 2013, 49(16):34863496. ［24］ Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acuteonchronic liver failure［J］. Hepatology, 2011, 53(3):774780. ［25］ Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases［J］. J Clin Oncol, 2010, 28(19):31993202.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[13]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[14]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[15]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.

Progress of prevention and cure of chemoradiotherapy-related hepatitis B virus reactivation

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments